Background: The ability to predict the course of multiple sclerosis (MS) is highly desirable but lacking. Objective:To test whether the MS Severity Scale (MSSS) and global neuronal viability, assessed through the quantifi
Introduction
Multiple sclerosis (MS) is the most prevalent autoimmune disorder of the central nervous system (CNS), affecting more than two million people worldwide. 1 Its relapsing-remitting (RR) form, characterized by cycles of relapses of varying severity and length separated by remissions of different duration, 2 is the most common, $85% of cases, subtype. 3 Since MS is chronic, and given its average age of onset of late twenties, 4 some patients require years of treatment and assistance. Consequently, and due to its variable course and cost of treatment, 5, 6 it may be helpful to ascertain severity of course early in the disease. 7, 8 Several demographic, clinical and magnetic resonance imaging (MRI) methods for monitoring the disease have been used with variable success, but there is still no universal assessment gold standard. 2, [9] [10] [11] [12] [13] The Expanded Disability Status Scale (EDSS) is the most commonly used scoring system for clinical progression of MS. 14 Unfortunately, it is susceptible to several limitations, primarily: i) inter-rater subjectivity; ii) nonlinearity; insensitivities to iii) cognitive impairment and iv) disease duration; and v) sensitivity to focal pathologies that cause lasting deficits without compromising overall neural integrity, for example, in the cord. 15 The MS Severity Scale (MSSS), that uses a probabilistic method to assign a disease severity score on the basis of EDSS score adjusted for disease duration, aims to address the nonlinearity issue as well as yield, by multiplying a patient's MSSS score by 10, the prevalence of an EDSS subgroup within a population. 16 It has already been established that neural damage is the primary cause of irreversible disability in MS. 17 Moreover, regional declines in the MR marker, the amino acid derivative N-acetylaspartate (NAA) have correlated better with clinical disability than other imaging metrics. [18] [19] [20] [21] [22] Since MS pathology is diffuse throughout the CNS 23 it is perhaps not surprising that the global whole-brain NAA concentration (WBNAA), a marker for global neuronal integrity, 24 has also shown substantial deficits in patients with RRMS relative to matched controls, [24] [25] [26] that correlated with disease duration. 27 The variable course of MS, its duration, cost of medications and their side effects make early characterization of disease status and course desirable. 7, 8, 28 This motivated us to test if the WBNAA and the MSSS, that reflects clinical disability accumulation rate, 16 yield similar predictive (or complementary) power and assessment. To test this hypothesis we compared the MSSS and its WBNAA analog -annual loss rate (ÁWBNAA) -in a cohort of benign (defined as EDSS 3.0 after 15 or more years 3, 29, 30 ) and patients with non-benign MS of similar disease duration. Such cohorts were chosen since long disease durations retrospectively characterize their courses.
Materials and methods Subjects
This is a retrospective study of 27 patients with benign MS: four male, 23 female, 50.3 AE 10.1 years old (mean AE standard deviation), disease duration from first symptom of 22.9 AE 6.8 years, and EDSS score of 3.0 or less (median 2.0, range: 0-3.0). To this cohort we matched (in terms of gender, age and disease duration) a group of 34 'non-benign' MS patients: 14 male, 20 female, 53.4 AE 8.9 years old, disease duration of 23.4 AE 7.1 years and EDSS score of more than 3.0 (median 4.5, range: 3.5-7.0). All benign patients exhibited a RR course. Of the non-benign patients, 16 exhibited a RR course, 11 were secondary progressive, five progressive-relapsing and two were primary progressive. The rationale for this enrollment was that given the variable course of the disease, there exists a (retrospective) clinical gold standard for these two cohorts: patients who are currently 'benign' very likely have always been so. Conversely, all other patients became 'non-benign' when their EDSS score exceeded 3.0 and they were deemed to have had such course in the preceding years as well. All patients had been relapse-and steroid-free for at least 3 months before their scan and clinical evaluation that included EDSS rating administered by the same neurologist. Seventeen healthy controls: eight male, nine female, 34.0 AE 6.0 years old were also scanned. All participants gave an Institutional Review Board-approved written consent.
MRI brain volume,V B
All experiments were done in a 3T Allegra head-only MRI scanner (Siemens AG, Erlangen, Germany) using a transmit-receive head-coil. After placing each subject into the scanner, its field homogeneity was adjusted over the head using our chemical shift imaging based an automatic shim procedure 31 to yield consistent 27 AE 4 Hz water linewidth in under 5 min. This was followed by sagittal T 1 -weighted Magnetization Prepared Rapid Gradient Echo (MP-RAGE) (TE/ TR/TI: 3.49/2150/1000 ms, 7 flip angle, 144 slices 1.1 mm thick, 256 Â 224 matrix and 256 Â 256 mm 2 fieldof-view (FOV)) MRI for brain volumetry; and axial dual echo proton density (PD)/T 2 -weighted turbo spin echo (TR/TE1/TE2: 3980/14/108 ms, 'turbo factor' of 7, 250 Â 250 mm 2 FOV, 256 Â 256 matrix, 40 slices, each 4 mm thick, aligned along the inferior border of the corpus callosum) MRI for lesion volumetry. Imaging ended with an axial post-contrast 2D T 1weighted sequence of 3 mm slice thickness (co-aligned with the preceding PD and T 2 ) MRI.
Subjects' brain parenchyma volume, V B , was segmented from the MP-RAGE images with our FireVoxel package. 32 It starts by placing a 'seed' region in periventricular white matter to obtain its average signal intensity, I WM . Following selection of all pixels at or above 55% of I WM (but below 135% to exclude fat), a brain mask is constructed for each slice in three consecutive steps: (i) morphological erosion; (ii) recursive region growth retaining pixels connected to the 'seed'; and (iii) morphological inflation to reverse the effect of erosion. Pixels of intensity under 55% of I WM were defined as cerebrospinal fluid (CSF). Masks were truncated at the foramen magnum to include the brain stem and cerebellum but not the cord. Finally, V B was the pixel volume Â their number in the masks. The precision of this approach was recently established at 3.4%, 32 on par with other commercially available brain volume segmentation methods. [33] [34] [35] Lesion volumes were outlined on the PD and post-contrast T 1 -weighted MRI using a semi-automatic thresholding contour software AMIRA 3.1.1 (Mercury Computer Systems Inc).
Intracranial volume,V IC
Intracranial volumes, V IC , were obtained from the MP-RAGE images using MRIcro, a free downloadable software package: http://www.mricro.com. 36 It employs a brain extraction tool to skull-strip the intracranial surface using a deformable model. 37 The process estimates the threshold between the brain and CSF, determines the head's center of gravity C, constructs a small tessellated surface F (initially a sphere) centered at C and incrementally adjusts the vertices of F to balance its smoothness and the desired signal intensity criteria. A volume-of-interest masking the extracted brain (see Figure 1 ) was then used to calculate the intracranial volume, V IC . The fractional brain parenchyma volume, fBPV (in %) was then defined as V B /V IC Â 100.
WBNAA quantification
The global brain NAA amount, Q NAA , was obtained with a non-localizing TE/TI/TR ¼ 0/940/10 4 ms 1 H-MRS sequence. 38 Its long TR»T 1 and short TE&0 ensure insensitivity to possible T 1 and T 2 variations, which are typically unknown, especially in pathologies. Absolute quantification was done against a reference 3 l sphere of 1.5 Â 10 -2 mole NAA in water as: 38
where V 180 R andV 180 S are the transmitter voltages for non-selective 1 ms-long 180 inversion pulses on the reference and subject, reflecting by reciprocity their relative coil sensitivity.
The subject and reference NAA peak areas, " S S and " S R , were obtained by averaging the results from manual phasing and selection of the NAA peak limits of integration (as shown in Figure 1 ) by four blinded operators. A result more than two average standard deviations (for the four readers' over all 61 patients, $8%) from the mean for that patient, from any of the readers, was rejected. If more than one result was rejected that entire set was excluded.
Note that although other metabolites, for example macromolecules and other N-acetyl-bearing species, may also resonate about 2.01 ppm, 39, 40 their contribution to the peak area is estimated at less than 10%. 40 Finally, while several other metabolites are also visible in the whole-head 1 H MR spectrum, as shown in Figure 1 , since the sequence is non-localizing, only the NAA is implicitly localized by its biochemistry to only the brain, whereas the others are present in all tissue types.
To normalize for differences in brain size among subjects, Q NAA was divided by the brain parenchyma volume, V B , (vide supra) to yield the whole-brain NAA concentration:
a specific, brain size-independent metric. Its inter-and intra-subject variability in younger healthy individuals has been shown to be better than AE 8%. 41 Since the MSSS takes into account disease duration, it is related to the rate of EDSS change. Consequently, it is appropriate to compare it with an analogous NAA rate metric, for example the average annual wholebrain NAA loss. Even though only one WBNAA point was acquired per patient in this study, the average annual projected rate of global change (analogous to the MSSS the rate of EDSS change) in the i-th patient can still be estimated assuming that: i) at first symptom their WBNAA i was similar to the average of healthy contemporaries, WBNAA ¼ 12.2 mM reported previously, 41 as well as in this study; and that therefore, ii) the time elapsed since ÁT i is a good approximation of disease duration; and iii) WBNAA decline is monotonic at a constant rate, given by: 27
It is also appropriate to consider an analogous tissue fraction rate metric, estimated subject to the assumption that annual brain atrophy due to normal aging is linear, and any excess over the reported rate of 0.33%/year for healthy individuals 42 is related to MS. This excess annual atrophy, ÁfBPV, was calculated based upon the controls' average, fBPV of 87.1% at 34 years as:
where age i is the i-th patient age in years and fBPV i their fractional brain parenchymal volume.
Statistics
The patients' EDSS, MSSS, ÁWBNAA, fPBV, ÁfBPV T 1 -and T 2 -lesion loads were summarized as means AE standard deviation. Comparisons between the groups were made using a Mann-Whitney test and confirmed with an unequal variance t-test. The set of results found to be significant by Mann-Whitney were exactly the same as those found significant by the t-test.
Results
Age and disease duration did not differ between the benign and non-benign groups. None of the WBNAA data sets had to be rejected due to poor quality. Representative MP-RAGE T 1 -weighted MRI of benign and non-benign patients are shown in Figure 1 with their corresponding whole-head 1 H spectra. Demographic, clinical and raw MR data for each patient is included in Table 1 . Dot plots of their EDSS, MSSS, ÁWBNAA and ÁfBPV, are shown in Figure 2 . Note the N-acetylaspartate (NAA) peak at 2 ppm, lipids suppression and that of the other metabolites peaks (most notably the glutamate (Glu), total creatine (Cr) and total choline (Cho)); only NAA is implicitly localized by its biochemistry to just the brain. Subjects' NAA peak area, S S (hatched), for Equation (1) was obtained by integration.
Similarly, the 0.10 AE 0.16 mM/year ÁWBNAA for the benign and 0.11 AE 0.12 mM/year in the non-benign group are not significantly different from each other (p > 0.7).
Each patient's ÁWBNAA is plotted against their MSSS in Figure 3 . Based on ÁWBNAA statistics from the 27 benign patients, we define a cutoff of 0.42 mM/year (the mean of 0.10 mM/year decline rate plus two 0.16 mM/year standard deviations). Any ÁWBNAA below this cutoff, indicates 'benign', whereas above it is 'non-benign'. Likewise, an MSSS to the left of the 2.0 cutoff, corresponding to its accepted 20% prevalence, 29, 30 indicates 'benign' and to its right, 'non-benign'. Figure 3 shows the MSSS to be both very sensitive to ( Figure 3 . The fBPV, an index of brain atrophy, was significantly higher in controls, 87.1 AE 4.5, than in both patient groups (p < 0.001), but not significantly different between the benign and non-benign groups (77.2 AE 7.4%, 76.6 AE 8.8%, p > 0.7). There was no significant difference between the ÁfBPV of benign patients, 0.22 AE 0.35%/year, and that of the nonbenign patients 0.20 AE 0.44%/year (p > 0.8). In analogy to the ÁWBNAA, we define a ÁfBPV threshold of 0.92%/year (0.22%/year of the benign patients plus two 0.35%/year standard deviations), below which a patient's course is deemed 'benign', as shown in Figures 2 and 3 . Here too, even though ÁfBPV exhibits 100% sensitivity to benign MS, it has very low ($3%) specificity.
Although the two patient groups differed significantly in their T 1 -hypointense lesion loads, 2.2 AE 2.2 cm 3 in the benign versus 4.4 AE 5.5 cm 3 in the nonbenign group (p ¼ 0.029), their respective T 2 -hyperintense lesion loads, 6.4 AE 5.4 cm 3 and 8.5 AE 7.9 cm 3 , were not different (p > 0.1).
Discussion
Though important for improving the efficacy of care, there remains no prospective metric for early prognosis of MS course. 8 Therefore, we chose our cohort to comprise patients who have gone through a long (15þ 92%/year, based on the benign cohorts' average þ2 standard deviations, are considered benign (arrows). Note that EDSS and MSSS in benign patients are significantly lower than non-benign, but that there is no clear difference in either ÁWBNAA or ÁfBPV between the two cohorts.
years) disease duration, rendering their current clinical status a retrospective gold standard for their overall past course: either benign or non-benign. Since neural damage is the major cause of permanent disability in patients with MS, 18, [43] [44] [45] and because benign MS is characterized by a mild clinical course, it is likely therefore that markers sensitive to each would provide similar clinical assessments. Unfortunately, the data do not support the hypothesis, as reflected by disparate sensitivity and specificity characteristics. There may be several explanations for the difference between clinical disability and WBNAA deficits. First, patients with the benign course may have more effective compensatory mechanisms than non-benign patients. Second, they may have had lesions evolving in clinically silent brain regions. Third, the classification system to differentiate benign from non-benign has a sharp cutoff at 3.0, rendering a patient with an EDSS of 3.5 'nonbenign'. The classification depends on a 0.5 EDSS unit difference that comprises the distinction between 'mild disability in three or four functional systems' versus 'more than minimal disability in several others'. 14 Indeed, as seen in Figure 2a , 13 out of 61 (21%) patients have an EDSS score between 3.0 and 3.5. Although the same neurologist evaluated all these patients, another clinician, or the same one at a different time, may return a different score, potentially switching a 'borderline' patient's classification. The composition of the cohort presents another potential confounding variable in that the RRMS benign patients are being compared with non-benign patients of several different phenotypes. There was, however, no difference between the non-benign subgroups in terms of their EDSS, MSSS ÁWBNAA or fBPV, although this may be attributable to the relatively small number, 16 or less, of patients in each of these nonbenign subgroups.
That the ÁWBNAA of benign and non-benign patients were not significantly different may indicate that, on average, individuals suffer the same amount of diffuse neurodegeneration in either clinical classification. That their raw fBPVs and ÁfBPVs, shown in Figure 3 , are similar, is non-specific and can be from any of the processes of which brain atrophy is the end stage. These results also highlight the MS paradoxes using other MR metrics, including higher lesion loads 46 and contradicting brain atrophy [47] [48] [49] in benign than in more disabled patients.
The lack of longitudinal studies in benign MS translates to vague long-term outcomes. To date, the longest, a 21-year study of 47 originally benign patients (by a similar definition), showed that only seven (15%) were still benign, 10 (21%) had died with significant MS-related disability and eight (17%) died of non-MS related causes. The remaining 22 all required ambulatory assistance. 50 The significant neuroaxonal injury in both benign and non-benign MS reflected by ÁWBNAA in this study is consistent with that conclusion. Moreover, although ÁWBNAA implicitly assumes that the loss is linear throughout the disease duration, it is likely a good approximation despite possible fluctuations or individual disease course heterogeneity. While measurable axonal damage has been shown to occur already at first symptom 25 (the starting point here), overall values of WBNAA loss in the benign group have been similar to those extrapolated from non-benign patients of much shorter disease durations. 51 This linear extrapolation indicates that there is no dominant NAA loss either very early or very late in the disease course.
Although the MSSS may be more sensitive than EDSS to differences in disease progression, more studies are needed to establish its stability over time. In a small study the MSSS scores were reported to be stable in nine out of 10 patients over time. 16 However, the EDSS in that study was assessed using a standardized protocol that may have reduced fluctuations in these scores, leading to an apparently stable MSSS. Although a study aiming at replicating these findings in a large cohort is currently underway, 52 its results are not yet disseminated.
This study is not without some limitations, however. First, the volume of interest of the WBNAA method is essentially the whole head for reasons of spatial coverage (sensitive to global diffuse neurodegeneration) and speed ($2.5 min/scan). Consequently, global NAA changes smaller than 6-8% are beneath its detection threshold and, therefore, regional NAA differences, for example in T 1 -hypointense lesions, are 'averaged out', or lost to partial volume averaging. Using alternative multi-slice 3D multi-voxel 1 H-MRS methods may overcome this problem at the expense of less than 70% brain coverage versus greater than 90% for WBNAA. 53, 54 Second, since this is a cross-sectional study of patients diagnosed retrospectively, NAA loss rates are only estimates contingent on the veracity of the underlying assumptions -primarily those of known date of onset and a monotonic decline thereafter. It is noteworthy, however, that the need for a decade and a half of follow-up to just establish a retrospective benign/non-benign course may render a longitudinal study both difficult and costly. Third, we do not have additional cognitive measures on any of the patients in either patient cohort, despite the fact that these metrics are gaining in acceptance as necessary to better define the various MS phenotypes. 8 Finally, we do not account for (possible) effects of treatment, its type, dose, length or changes in its regimen in these patients, due in part to their long disease duration.
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